Donald E. Stull
YOU?
Author Swipe
View article: Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion
Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion Open
Background Diffuse leptomeningeal glioneuronal tumor (DL-GNT) is a rare disease which is more often diagnosed in children and adolescents than adults. Activation of the MAPK/ERK pathway is implicated in the majority of cases, and BRAF fusi…
View article: 0856 Real-World Patient Insights on Low-Sodium Oxybate for Idiopathic Hypersomnia: Interim Results from LYRICAL
0856 Real-World Patient Insights on Low-Sodium Oxybate for Idiopathic Hypersomnia: Interim Results from LYRICAL Open
Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia (IH). To…
View article: 0858 Real-World Experience and Satisfaction with Low-Sodium Oxybate in Narcolepsy: Interim Results from LYRICAL
0858 Real-World Experience and Satisfaction with Low-Sodium Oxybate in Narcolepsy: Interim Results from LYRICAL Open
Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia. T…
View article: Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials
Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials Open
Objectives SLE significantly impairs health-related quality of life (HRQoL). In this post hoc analysis, structural equation modelling was used to examine the ‘causal cascade’ of interaction between anifrolumab, disease activity and patient…
View article: Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial
Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial Open
In this study, arformoterol treatment significantly improved HRQoL reflected by SGRQ. For the analysis performed on these data, arformoterol may be particularly effective in improving lung function and reducing hospitalizations among patie…
View article: Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria
Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria Open
Categorical UAS7TD disease states can discriminate between measures when considering the impact of urticaria activity. Using five categorical disease states could simplify clinical assessment and monitoring of treatment efficacy.
View article: Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies Open
Improvement in sleep was reported after the first dose of omalizumab. Sleep continued to improve throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatme…
View article: Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria Open
In this, the first economic evaluation of omalizumab in CSU from a UK societal perspective, omalizumab consistently represented a treatment option with societal benefit for CSU in the UK across a range of scenarios.
View article: EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria
EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria Open
The results suggest that EQ-5D utility scores increase with decreasing urticaria activity. EQ-5D utility scores enable the health-related quality of life of CSU patients to be compared with that of patients with other diseases.